Firma CatalYm, Autor bei PR-Web

CatalYm Presents Expanded Clinical and New Preclinical Data from

Posted on 1. March 20221. March 2022 by Firma CatalYm Posted in Research / Development Tagged biomarker, cancer, cell, cells, clinical, ctl, exploration, gdf, gdfather, monotherapy, patients, research, therapy, treatment, with

CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product candidate, the GDF-15 neutralizing antibody […]

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

Posted on 12. November 202112. November 2021 by Firma CatalYm Posted in Research / Development Tagged cancer, cell, cells, clinical, ctl, gdf, immunotherapy, medical, monotherapy, new, patients, strong, therapy, treatment, with

First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1 Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor microenvironment Preclinical in vivo study validates […]